See every side of every news story

Published 3 months ago • loading... • Updated 3 months ago

Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail

Summary by Clinical Trials Arena

Sanofi is also investigating balinatunfib in rheumatoid arthritis, Crohn's disease and ulcerative colitis.The post Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail appeared first on Clinical Trials Arena.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

Clinical Trials Arena

Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail

Sanofi is also investigating balinatunfib in rheumatoid arthritis, Crohn's disease and ulcerative colitis.The post Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail appeared first on Clinical Trials Arena.

3 months ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated3 months agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in 3 months ago on Thursday, April 24, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.